BofA says Hims’ semaglutide compounding opportunity may be shorter than expected

BofA notes that yesterday morning, the FDA issued a new decision determining that the shortage of Eli Lilly’s (LLY) tirzepatide was resolved. While also noting that Hims & Hers (HIMS) does not dispense tirzepatide, so yesterday morning’s decision “does not directly impact the company or its GLP-1 sales,” the analyst argues that the news “runs counter to consensus expectations and implies (all else equal) that the duration of the semaglutide compounding opportunity may be shorter than some expected.” The firm, which thinks there is “less likelihood of material upside revisions to 2025 revenue,” which also “runs counter to the substantial upside revisions” seen for Hims to date, maintains an Underperform rating on the shares.